Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data Fabrizio De Benedetti, Hermine Brunner, Nicola Ruperto, R Cuttica, Clara Malattia, Rayfel Schneider, Patricia Woo, Despina Eleftheriou, Eileen Baildam, Ruben Burgos-Vargas, Pavla Dolezalova, Stella M Garay, Rik Joos, Nico Wulffraat, Zbyszek Zuber, Francesco Zulian, Carine...
متن کاملPReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial C Malattia, N Ruperto, E Palmisani, S Pederzoli, A Pistorio, HI Brunner, R Cuttica, I Calvo, SM Garay, D Eleftheriou, C Wouters, J Wang, C Devlin, D Lovell, A Martini, F De Benedetti, A Ravelli, PRCSG an...
متن کاملSafety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
Results A total of 39 patients (21 boys and 18 girls) were included in this Median age was 7,5 years (range; 3 to 15 years) and median disease duration was 4,2 years (range; 0.5 to 8,3 years). A total of 16 of the 39 patients (25%) entered 52 weeks of continuous tocilizumab treatment. The frequently observed non-severe adverse events were nasopharyngitis, upper respiratory tract infection and g...
متن کاملEfficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
Results 18 patients aged 4-15 years were included. The median disease duration at treatment onset was 4.7 years (0.48.8). The median dose of prednisone at TCZ onset was 0.63mg/kg/d. Four patients were also on MTX. Fourteen patients had previously failed to respond one or several biologics, including anti-TNF alpha in 10 cases, anakinra in 14 and canakinumab, in 4. All patients but 4 had active ...
متن کاملSafety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
Results Until 31.12.2014 60 sJIA patients were included in BiKeR in which treatment with tocilizumab was started. The mean age at onset was 4.6 (median 3.3) years and the mean age at baseline was 9.4 (median 9.8) years and mean disease duration was 4.7 (median 3.6) years. Only 20.3% of patients were treated with tocilizumab in the first two years of their disease. Pre-treatment with NSAIDs was ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2011
ISSN: 1546-0096
DOI: 10.1186/1546-0096-9-s1-p164